<div id="readability-page-1"><div> SHANGHAI, April 1, 2026 /PRNewswire/ -- MedJ, China's leading medical media platform, today officially launched its dedicated International Platform: a first-of-its-kind authoritative English-language hub delivering real-time, contextualized insights into China's fast-evolving healthcare and biomedical landscape for clinicians, researchers, and industry stakeholders worldwide. <img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2947042/image.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="225" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2947042/image.jpg"/> The launch comes as China's global influence in biomedical research reaches unprecedented heights. The 2025 NCS Hospital Index, a bibliometric ranking from the editorial teams of Nature, Cell, and Science (collectively NCS), found 41 hospitals from Chinese mainland ranked in the global top 100 for 2025 publications in the three flagship journals and their high-impact sub-journals. This figure outpaced the U.S. (29 hospitals) to claim the No.1 global spot, underscoring the rising authority of Chinese medical institutions on the world's top academic stage.A trusted leader in China's medical media for over a decade, MedJ serves 3 million registered healthcare professionals, reaches 10 million subscribers, and partners with 20,000+ leading medical experts and 10,000+ hospitals nationwide. Its new International Platform eliminates longstanding barriers for global peers: fragmented information sources, language gaps, and missing critical context around China's medical advances.The platform launches with four core editorial sections:<ul><li>Innovation Therapy: Full-lifecycle updates on novel drugs, devices, and regulatory milestones in China</li><li>Doctors: Exclusive perspectives from China's top clinical and research leaders</li><li>Conferences: Frontline reporting from key global medical congresses</li><li>Webinar: Live, two-way academic exchanges between Chinese and global medical communities</li></ul>As China solidifies its rightful place in global healthcare, MedJ's International Platform stands as an open, inclusive gateway for cross-border collaboration. All the critical insights you need, in one centralized destination.Visit [MedJ.cn] to explore.Contact: MedJPhone: +86 21 58545118Mail: medjservice@medj.cn <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNC0wMSZzbj1DTjIzNTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNC0wMSZzbj1DTjIzNTA1"/> View original content to download multimedia:https://www.prnewswire.com/news-releases/medj-unveils-international-platform-your-trusted-gateway-to-chinas-fast-growing-biomedical-landscape-302730775.htmlSOURCE MedJ</div></div>

科创医药ETF工银

南方恒生生物科技ETF(QDII)

天顺股份

MedJ，作为中国领先的医疗媒体平台，推出了其国际平台，这是一个提供中国医疗和生物医学领域实时洞察的英语中心。该举措旨在为全球临床医生和研究人员弥补信息差距，突显中国在生物医学研究中日益增长的影响力，正如其在 2025 年 NCS 医院指数中的顶级排名所示。该平台设有创新疗法、专家观点、会议报道和网络研讨会等板块，促进医疗领域的跨境合作

MedJ Unveils International Platform: Your Trusted Gateway to China's Fast-Growing Biomedical Landscape

MorningStar

易方达中证生物科技主题ETF

方正富邦中证医药及医疗器械创新ETF

医疗器械ETF永赢

创新药

天弘国证生物医药ETF

生物科技ETF基金

平安中证医疗创新ETF

博时恒生医疗保健(QDII-ETF)

华安恒生生物科技ETF

博时恒生港股通创新药精选ETF

招商中证全指医疗器械ETF

招商中证生物科技主题ETF

国泰中证生物医药ETF

华夏中证生物科技主题ETF

广发中证香港创新药(QDII-ETF)

开普检测

富国恒生港股通创新药及医疗保健ETF

MedJ 推出国际平台：您可信赖的通往中国快速发展的生物医学领域的门户